Findings from the successful trials of a new, multi-compound, cannabis medicine look set to deliver a major breakthrough for the
The UK economic growth faces a paradox of two seemingly opposing pressures, yet both may be resolved by moving in
Sorting Evidence from Anecdote As global cannabis research accelerates, the number of published studies has never been higher, but not
Cannabis is now one of the most frequently discussed therapeutic agents in modern medicine, driven by expanding access programmes and
German pharmaceutical company Vertanical believes it is on course to deliver the first ‘whole-plant’, cannabis medicine with international approval. After
At its core, Standard Seed AI’s technology has the power to scientifically validate the entourage effect, streamline drug discovery, and drastically reduce the time and cost of bringing cannabis-based medicines to market.
In response to this growing exodus of promising biotech firms, the European Union has proposed a new Biotech Act, as part of ongoing efforts by the European Commission to strengthen the continent’s biotechnology and biomanufacturing sectors, which have struggled with fragmented rules and sluggish approval processes.
UK-based cannabinoid pharmaceutical company Ananda Pharma has received ethics approval for a Phase 1 clinical study for its lead compound in Australia.
UK-listed medical cannabis producer Celadon Pharmaceuticals is struggling to emerge from its precarious financial position after months of turmoil.
Kingdom Therapeutics, a UK-Irish biotech company, has passed a ‘major milestone’ in its ambitious journey towards launching clinical trials into cannabis and Autism Spectrum Disorder (ASD)
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
